Skip to main content


Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study

Fig. 1

Maximum percent decrease in evaluable lesions: (a) Injected lesions, (b) Uninjected non-visceral lesions, and (c) Visceral lesions. Lesion measurements per investigator. Evaluable indicates at least 2 assessments with valid measurements. Uninjected lesion indicates baseline or new lesions never known to be injected. Safety analysis set consisted of the patients who received at least one dose of study therapy

Back to article page